| Name | Role | Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Marcella K. Ruddy | Chief Medical Officer | 2026-05-04 | 1,065 | $30.00 | $31.95kSell |
| Marcella K. Ruddy | Chief Medical Officer | 2026-04-01 | 1,000 | $31.05 | $31.05kSell |
| Peter McNamara | Chief Scientific Officer | 2026-03-06 | 215 | $35.00 | $7.53kSell |
| Marcella K. Ruddy | Chief Medical Officer | 2026-03-06 | 10,000 | $30.00 | $300.00kSell |
| Peter McNamara | Chief Scientific Officer | 2026-03-06 | 215 | $14.71 | $3.16kBuy |
| Peter McNamara | Chief Scientific Officer | 2026-03-06 | 6,047 | $30.00 | $181.41kSell |
| Peter McNamara | Chief Scientific Officer | 2026-03-06 | 2,500 | $2.38 | $5.95kBuy |
| Peter McNamara | Chief Scientific Officer | 2026-03-04 | 1,650 | $25.00 | $41.25kSell |
| Peter McNamara | Chief Scientific Officer | 2026-03-03 | 1,649 | $22.06 | $36.38kSell |
| Alise Reicin | Chief Executive Officer | 2026-02-11 | 2,500 | $21.10 | $52.75kBuy |
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| Timothy A. Springer | 31.93% | 6,024,338 | $168.02M | Insider |
| Bruce Booth | 29.50% | 5,567,289 | $155.27M | Insider |
| Braden Michael Leonard | 26.00% | 4,905,068 | $136.80M | Insider |
| Atlas Venture Fund X LP | 25.21% | 4,756,478 | $132.66M | Insider |
| Clarus Lifesciences III LP | 23.55% | 4,443,487 | $123.93M | Insider |
| Atlas Venture Associates X LP | 19.66% | 3,710,052 | $103.47M | Insider |
| Scott Requadt | 15.70% | 2,962,325 | $82.62M | Insider |
| Blackstone Holdings II LP | 15.70% | 2,962,325 | $82.62M | Insider |
| Aberdeen Group PLC | 6.05% | 1,141,824 | $31.85M | Institution |
| Atlas Venture Opportunity Fund I LP | 4.30% | 810,811 | $22.61M | Insider |